We serve Chemical Name:4-Chloro-2-fluorobenzyl chloride CAS:87417-71-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Chloro-2-fluorobenzyl chloride
CAS.NO:87417-71-8
Synonyms:4-Chloro-1-(chloromethyl)-2-fluorobenzene;Benzene, 4-chloro-1-(chloromethyl)-2-fluoro-;G1R DG BF;4-Chloro-2-fluorobenzyl chloride;2-Fluoro-4-chlorobenzyl chloride
Molecular Formula:C7H5Cl2F
Molecular Weight:179.019
HS Code:2903999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:208.5±25.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.526
PSA:
Exact Mass:177.975235
LogP:2.69
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Chloro-1-(chloromethyl)-2-fluorobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Fluoro-4-chlorobenzyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,G1R DG BF Use and application,4-Chloro-1-(chloromethyl)-2-fluorobenzene technical grade,usp/ep/jp grade.
Related News: Novak noted that the research team did see some improvement in standard brain function tests given to a smaller group of trial participants who had actually been diagnosed with Alzheimer’s. 4-Chloro-2-fluorobenzyl chloride manufacturer AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 4-Chloro-2-fluorobenzyl chloride supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 4-Chloro-2-fluorobenzyl chloride vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 4-Chloro-2-fluorobenzyl chloride factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).
